Clinical Trial Update: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

Phase I master protocol trial evaluating a novel combination therapy for patients with relapsed or refractory aggressive B-cell lymphomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Lymphoma, B-Cell | EARLY_Phase 1 | Status: RECRUITING